ES2556816T3 - Hidrogeles tixotrópicos a base de alfa-lactalbúmina, método de preparación y uso de los mismos - Google Patents
Hidrogeles tixotrópicos a base de alfa-lactalbúmina, método de preparación y uso de los mismos Download PDFInfo
- Publication number
- ES2556816T3 ES2556816T3 ES12722748.6T ES12722748T ES2556816T3 ES 2556816 T3 ES2556816 T3 ES 2556816T3 ES 12722748 T ES12722748 T ES 12722748T ES 2556816 T3 ES2556816 T3 ES 2556816T3
- Authority
- ES
- Spain
- Prior art keywords
- lactalbumin
- suspension
- hydrogel
- preparation
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 102000004407 Lactalbumin Human genes 0.000 title abstract 7
- 108090000942 Lactalbumin Proteins 0.000 title abstract 7
- 235000021241 α-lactalbumin Nutrition 0.000 title abstract 7
- 238000000034 method Methods 0.000 title description 3
- 230000009974 thixotropic effect Effects 0.000 title 1
- 239000000499 gel Substances 0.000 abstract description 4
- 238000013019 agitation Methods 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 abstract 5
- 230000002378 acidificating effect Effects 0.000 abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000008020 evaporation Effects 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 7
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/08—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
- A23L29/284—Gelatin; Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/04—Thixotropic paints
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Procedimiento de preparación de un hidrogel de α-lactalbúmina a partir de una suspensión acuosa de α- lactalbúmina a una concentración Ca-La comprendida entre 5 y 60 mg/mL, que comprende las etapas siguientes: a) la puesta en suspensión de α-lactalbúmina en una solución acuosa ácida que tiene una fuerza iónica inferior o igual a 60 mM; consistiendo dicha puesta en solución en: (a1) la preparación de una solución acuosa ácida que tenga una concentración de protones expresada en mM, determinada por la suma: (valor numérico de Ca-La expresado en g/L) + 10; (a2) la suspensión de la α-lactalbúmina en dicha solución acuosa ácida; y (a3) si fuera necesario, el ajuste del pH a un valor comprendido entre 1,5 y 2,5; (b) la formación del gel a partir de dicha suspensión de α-lactalbúmina obtenida al final de la etapa a); realizándose dicha formación del gel en las condiciones siguientes: - a una temperatura inferior a 60ºC; - bajo una agitación que tenga una intensidad definida por un número de Reynolds comprendido entre 37 y 1000; - durante 10 horas a 1 semana, y - en ausencia de evaporación de agua de dicha suspensión de α-lactalbúmina.
Description
5
10
15
20
25
30
35
40
45
50
La Figura 3 representa el seguimiento de la reestructuración a 15ºC en el transcurso del tiempo de un hidrogel de a-La de 20 mg/mL y 30 mM de NaCl después de una desestructuración con gran deformación con un gradiente de cizalladura de 10 s-1; el módulo elástico G’ se representa con círculo lleno y el módulo viscoso G’’, en circulo vacío.
La Figura 4 ilustra el fin del seguimiento de la reestructuración a 15ºC en el transcurso del tiempo de un hidrogel de a-La de 20 mg/mL y 30 mM de NaCl después de una desestructuración con gran deformación con un gradiente de cizalladura de 10 s-1 (etapa 6), después la etapa 7 de desestructuración con cizalladura armónica con amplitud de deformación creciente y, por ultimo, la etapa 8 de seguimiento de la recuperación de la consistencia con pequeña deformación.
La Figura 5 es una comparación de la cinética de reestructuración a 15ºC en el transcurso del tiempo de un hidrogel de a-La de 20 mg/mL y 30 mM de NaCl (etapa 6) después de una desestructuración con gran deformación con un gradiente de cizalladura de 10 s-1, (G’ se representa con triángulo lleno y G’’ con triangulo vacío) y (etapa 8) después de una desestructuración con pequeñas deformaciones de cizalladura armónica con amplitud de deformación creciente (G’ se representa con círculo lleno y G’’ con círculo vacío).
La Figura 6 representa el seguimiento de la desestructuración con cizalladura armónica con amplitud de deformación creciente a 15ºC en el transcurso del tiempo de un hidrogel de a-La de 20 mg/mL y NaCl 30 mM: identificación de la deformación crítica γc de aproximadamente 0,2 a partir de la cual comienza a aparecer la transición sol-gel (etapa 7).
La Figura 7 representa el seguimiento de la desestructuración y de la reestructuración a 15ºC en el transcurso del tiempo de un hidrogel de a-La con pequeñas deformaciones de cizalladura armónica; 20 mg/mL – NaCl 0 mM.
La Figura 8 representa el seguimiento de la desestructuración y de la reestructuración a 15ºC en el transcurso del tiempo de un hidrogel de a-La con pequeñas deformaciones de cizalladura armónica; 20 mg/mL – NaCl 60 mM.
La Figura 9 representa el seguimiento de la desestructuración y de la reestructuración a 15ºC en el transcurso del tiempo de un hidrogel de a-La con pequeñas deformaciones de cizalladura armónica; 40 mg/mL -NaCl 60 mM.
La Figura 10 compara los niveles de los módulos viscoelásticos G’ y G’’ en función de la fuerza iónica de NaCl y de la concentración de a-La: el módulo G’ para un hidrogel de 20 mg/mL se representa por discos llenos, el módulo G’’ para un hidrogel de 20 mg/mL de a-La se representa por discos vacíos, el módulo G’ para un hidrogel de 40 mg/mL de a-La se representa por triángulos llenos, el módulo G’’ para un hidrogel de 40 mg/mL de a-La se representa por triángulos vacíos. Los niveles se compararon con el mismo tiempo de reestructuración de 500 s de la etapa 3, correspondiente a la zona de reestructuración de cinética lenta.
La Figura 11 es una gráfica que compara los niveles de deformación crítica γc en función de la fuerza iónica de NaCl y de la concentración de a-La (discos vacíos para una concentración de a-La de 20 mg/mL y discos llenos para una concentración de a-La de 40 mg/mL). Para cada condición, el fenómeno de desestructuración es muy reproducible, lo que demuestra la gran capacidad del sistema para sufrir diversas solicitaciones de cizalladura sin sufrir modificaciones fisicoquímicas o de desnaturalización, cualesquiera.
La Figura 12 representa el seguimiento de la desestructuración y de la reestructuración a 15ºC en el transcurso del tiempo de dos hidrogeles de a-La de 20 mg/mL y NaCl 0 mM (el uno preparado a partir de a-La purificada, el segundo a partir de lactosuero enriquecido al 45% de a-La) con pequeñas deformaciones de cizalladura armónica. Se aplicaron diferentes procedimientos de seguimiento de la evolución de los módulos elásticos G’ (circulo lleno para el hidrogel preparado a partir de a-La purificada; triángulo lleno para el hidrogel preparado a partir de lactosuero enriquecido al 45% de a-La) y viscoso G’’ (círculo vacío para el hidrogel preparado a parir de a-La purificada; triángulo vacío para el hidrogel preparado a partir de lactosuero enriquecido al 45% de a-La) en función del tiempo y de la deformación impuesta (cruz); las solicitaciones aplicadas en el transcurso de las etapas 1 a 3 se detallan a continuación en el ejemplo 2.
La Figura 13 comprende dos clichés de tubos Ependorf que comprenden, de una parte un gel realizado según el protocolo de la tesis de C. Blanchet (B) y, de otra parte un hidrogel según la invención (A). El cliché de la izquierda muestra estos dos hidrogeles después de su preparación (los dos están en el extremo cónico de los tubos); el cliché de la derecha muestra estos dos hidrogeles después de la agitación, el hidrogel (A) según la invención está en la parte baja del tubo Ependorf mientras que el hidrogel (B) permanece en la parte superior (extremo cónico).
Ejemplo 1 – determinación de la gama de valores del número de Reynolds de la intensidad de agitación para la ejecución del procedimiento según la invención
ρ vd
El número de Reynolds representa la intensidad de la agitación; en un reactor agitado, es igual a Re =
µ
en donde:
-p es la masa volúmica del fluido mezclado, en Kg.m-3 ,
8
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1153077A FR2973648A1 (fr) | 2011-04-08 | 2011-04-08 | Hydrogels thixotropes a base d'alpha-lactalbumine, leur procede de preparation et leurs utilisations |
| FR1153077 | 2011-04-08 | ||
| PCT/FR2012/000138 WO2012136909A2 (fr) | 2011-04-08 | 2012-04-10 | HYDROGELS THIXOTROPES À BASE α-LACTALBUMINE, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS UTILISATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2556816T3 true ES2556816T3 (es) | 2016-01-20 |
Family
ID=46147468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12722748.6T Active ES2556816T3 (es) | 2011-04-08 | 2012-04-10 | Hidrogeles tixotrópicos a base de alfa-lactalbúmina, método de preparación y uso de los mismos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9724423B2 (es) |
| EP (1) | EP2693893B1 (es) |
| JP (1) | JP6099624B2 (es) |
| CA (1) | CA2832401C (es) |
| ES (1) | ES2556816T3 (es) |
| FR (2) | FR2973648A1 (es) |
| PL (1) | PL2693893T3 (es) |
| WO (1) | WO2012136909A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2973648A1 (fr) * | 2011-04-08 | 2012-10-12 | Commissariat Energie Atomique | Hydrogels thixotropes a base d'alpha-lactalbumine, leur procede de preparation et leurs utilisations |
| CN107320738B (zh) * | 2017-07-12 | 2020-06-12 | 福州大学 | 一种四氧化三锰-乳白蛋白纳米球及其制备与应用 |
| WO2019013651A1 (en) * | 2017-07-14 | 2019-01-17 | Hi-Aspect Limited | FIBILAR PROTEIN COMPOSITIONS AND USES THEREOF |
| US10800893B2 (en) | 2018-11-09 | 2020-10-13 | Regents Of The University Of Minnesota | Lactose-derived hydrogels and methods of producing the same |
| CA3060806A1 (en) | 2018-11-09 | 2020-05-09 | Winfield Solutions, Llc | Hydrogel comprising sugar and active agent for agricultural use |
| CA3060477A1 (en) | 2018-11-09 | 2020-05-09 | Windfield Solutions, Llc | Hydrogels as rheology modifiers and methods of making the same |
| FR3099648B1 (fr) | 2019-07-30 | 2023-01-13 | Centre Nat Rech Scient | Membrane échangeuse d’ions |
| FR3135352B1 (fr) | 2022-05-03 | 2024-04-26 | Commissariat Energie Atomique | Generateur d’electricite a base de fibres amyloïdes |
| AU2024299302A1 (en) | 2023-07-27 | 2026-02-05 | Centre National De La Recherche Scientifique | Composite materials functionalized with protein fibers comprising at least one amyloid structure |
| CN117122554A (zh) * | 2023-10-26 | 2023-11-28 | 中国农业大学 | 一种氧化还原酶活性药物载体制备及在关节炎中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0459566A1 (en) * | 1990-05-29 | 1991-12-04 | Unilever N.V. | Translucent thixotropic hygel |
| JPH04252144A (ja) * | 1991-01-25 | 1992-09-08 | Snow Brand Milk Prod Co Ltd | ホエー蛋白質溶液、それを用いたホエー蛋白質ゲル化物及び加工食品 |
| US6139900A (en) * | 1998-08-11 | 2000-10-31 | North Carolina State University | Method of forming whey protein products |
| NZ554743A (en) * | 2007-04-24 | 2009-12-24 | Fonterra Co Operative Group | Dairy product and process |
| US8834926B2 (en) * | 2008-08-08 | 2014-09-16 | University Of Delaware | Macromolecular diffusion and release from self-assembled β-hairpin peptide hydrogels |
| WO2010099185A2 (en) * | 2009-02-24 | 2010-09-02 | Nutrifam, Llc | Protein containing food stuffs |
| CN101878904B (zh) * | 2010-06-23 | 2013-01-09 | 华南理工大学 | 一种乳清蛋白凝胶状乳液的生产方法 |
| FR2973648A1 (fr) * | 2011-04-08 | 2012-10-12 | Commissariat Energie Atomique | Hydrogels thixotropes a base d'alpha-lactalbumine, leur procede de preparation et leurs utilisations |
-
2011
- 2011-04-08 FR FR1153077A patent/FR2973648A1/fr active Pending
-
2012
- 2012-04-10 ES ES12722748.6T patent/ES2556816T3/es active Active
- 2012-04-10 CA CA2832401A patent/CA2832401C/fr active Active
- 2012-04-10 EP EP12722748.6A patent/EP2693893B1/fr active Active
- 2012-04-10 WO PCT/FR2012/000138 patent/WO2012136909A2/fr not_active Ceased
- 2012-04-10 US US14/110,577 patent/US9724423B2/en active Active
- 2012-04-10 PL PL12722748T patent/PL2693893T3/pl unknown
- 2012-04-10 JP JP2014503188A patent/JP6099624B2/ja active Active
- 2012-05-15 FR FR1254465A patent/FR2973649B1/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| FR2973649B1 (fr) | 2013-10-25 |
| JP6099624B2 (ja) | 2017-03-22 |
| WO2012136909A2 (fr) | 2012-10-11 |
| CA2832401C (fr) | 2019-10-15 |
| FR2973649A1 (fr) | 2012-10-12 |
| JP2014512179A (ja) | 2014-05-22 |
| CA2832401A1 (fr) | 2012-10-11 |
| PL2693893T3 (pl) | 2016-05-31 |
| FR2973648A1 (fr) | 2012-10-12 |
| US20140221289A1 (en) | 2014-08-07 |
| WO2012136909A3 (fr) | 2012-11-29 |
| EP2693893B1 (fr) | 2015-10-21 |
| EP2693893A2 (fr) | 2014-02-12 |
| US9724423B2 (en) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2556816T3 (es) | Hidrogeles tixotrópicos a base de alfa-lactalbúmina, método de preparación y uso de los mismos | |
| Lozinsky | Cryostructuring of polymeric systems. 55. Retrospective view on the more than 40 years of studies performed in the AN Nesmeyanov Institute of Organoelement Compounds with respect of the cryostructuring processes in polymeric systems | |
| Balasooriya et al. | Applications of nano hydroxyapatite as adsorbents: a review | |
| Lovskaya et al. | Chitosan-based aerogel particles as highly effective local hemostatic agents. production process and in vivo evaluations | |
| US7108970B2 (en) | Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state | |
| Wang et al. | Stabilizing the oil-in-water emulsions using the mixtures of Dendrobium officinale polysaccharides and gum arabic or propylene glycol alginate | |
| Branco et al. | PVA-based hydrogels loaded with diclofenac for cartilage replacement | |
| AU2023202841B2 (en) | Method of estimating blood volume | |
| Zhao et al. | Improved gel properties of whey protein-stabilized emulsions by ultrasound and enzymatic cross-linking | |
| Paraskevopoulou et al. | Evaluation of polyurea-crosslinked alginate aerogels for seawater decontamination | |
| Chrzanowska et al. | Mesocellular silica foams (MCFs) with tunable pore size as a support for lysozyme immobilization: Adsorption equilibrium and kinetics, biocomposite properties | |
| Gago et al. | Protein adsorption performance of a novel functionalized cellulose-based polymer | |
| Loewe et al. | A combined ultrafiltration/diafiltration process for the purification of oncolytic measles virus | |
| Zuev et al. | Underused marine resources: sudden properties of cod skin gelatin gel | |
| Yan et al. | PEGDA hydrogel microspheres with encapsulated salt for versatile control of protein crystallization | |
| Liu et al. | Preparation of chitosan/β-cyclodextrin composite membrane and its adsorption mechanism for proteins | |
| Wang et al. | Novel Pickering high internal phase emulsion stabilized by food waste-hen egg Chalaza | |
| Zhang et al. | The Influence of Protein Components on Quinoa Protein–Xanthan Gum Complex Gels at Different pH Levels | |
| Wang et al. | Formation and characterization of β-lactoglobulin and gum arabic complexes: The role of pH | |
| WO2024259836A1 (zh) | 一种多糖球形凝胶树脂的制备方法 | |
| Zasońska et al. | Magnetic superporous poly (2-hydroxyethyl methacrylate) hydrogel scaffolds for bone tissue engineering | |
| Sun et al. | Rheological properties of the gels of biological surfactant sodium deoxycholate/amino acids/halide salts systems | |
| Yao et al. | Manufacture of bilayered composite hydrogels with strong, elastic, and tough properties for osteochondral repair applications | |
| CN103575792A (zh) | 梯度凝胶及其制备方法 | |
| Wu et al. | Laser-induced photothermal hydrogels promote the proliferation of MC3T3-E1 preosteoblasts for enhanced bone healing |